Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M.
Nomura M, et al. Among authors: andoh m.
Cancer Chemother Pharmacol. 2015 Aug;76(2):357-63. doi: 10.1007/s00280-015-2806-8. Epub 2015 Jun 20.
Cancer Chemother Pharmacol. 2015.
PMID: 26092324